APMONIA THERAPEUTICS announces a 2.5€ million financing to develop its lead candidate targeting solid cancers
Coave Therapeutics Strengthens Leadership Team with the Appointments of Catherine Mathis as Vice President Regulatory Affairs and Julien Berger as Head of Legal Affairs
Immutep Announces Investigator-Initiated Phase II Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma
Pharnext nomme Rob Quinn au poste de Directeur Financier
